Gador is an Argentine pharmaceutical company headquartered in Buenos Aires, Argentina, with a significant presence in the central nervous system (CNS) therapeutics market. The company develops and markets pharmaceutical products for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other CNS conditions[@gador2024].
Founded in 1935, Gador is one of Argentina's oldest and most established pharmaceutical companies. The company has evolved from a local distributor to a fully-integrated pharmaceutical company with manufacturing capabilities, research and development programs, and a regional presence across Latin America.
Company Profile
| Attribute | Details | |-----------|---------| | Headquarters | Buenos Aires, Argentina | | Founded | 1935 | | Focus Areas | CNS, Cardiovascular, Anti-infectives, Oncology | | Employees | ~1,500 | | Revenue | ~$200 million USD | | Stage | Commercial stage with R&D |
History and Development
Early History
Gador was founded in 1935 as a pharmaceutical import and distribution company. Over the decades, the company has evolved significantly:
1935-1970:
Established as pharmaceutical distributor
Expanded product portfolio through partnerships
Built national distribution network
1970-2000:
Established local manufacturing capabilities
Developed generic pharmaceutical portfolio
Expanded into international markets
...
Overview
Gador is an Argentine pharmaceutical company headquartered in Buenos Aires, Argentina, with a significant presence in the central nervous system (CNS) therapeutics market. The company develops and markets pharmaceutical products for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other CNS conditions[@gador2024].
Founded in 1935, Gador is one of Argentina's oldest and most established pharmaceutical companies. The company has evolved from a local distributor to a fully-integrated pharmaceutical company with manufacturing capabilities, research and development programs, and a regional presence across Latin America.
Company Profile
| Attribute | Details | |-----------|---------| | Headquarters | Buenos Aires, Argentina | | Founded | 1935 | | Focus Areas | CNS, Cardiovascular, Anti-infectives, Oncology | | Employees | ~1,500 | | Revenue | ~$200 million USD | | Stage | Commercial stage with R&D |
History and Development
Early History
Gador was founded in 1935 as a pharmaceutical import and distribution company. Over the decades, the company has evolved significantly:
1935-1970:
Established as pharmaceutical distributor
Expanded product portfolio through partnerships
Built national distribution network
1970-2000:
Established local manufacturing capabilities
Developed generic pharmaceutical portfolio
Expanded into international markets
2000-Present:
Built innovative R&D capabilities
Established neuroscience division
Developed specialty pharmaceutical focus
Neuroscience Programs
Alzheimer's Disease
Gador has a significant presence in Alzheimer's disease treatment:
Marketed Products:
Rivastigmine: Cholinesterase inhibitor for mild-to-moderate AD
Donepezil formulations: Various dosage forms
Combination therapies: Fixed-dose combinations in development
Development Pipeline:
Novel cholinesterase inhibitors
Disease-modifying approaches
Symptomatic treatments for cognition
Parkinson's Disease
The company has programs in Parkinson's disease:
Marketed Products:
Levodopa/Carbidopa formulations: Standard treatments
Dopamine agonists: Oral and transdermal formulations
Gador is a long-established Argentine pharmaceutical company with a strong presence in CNS therapeutics, particularly for Alzheimer's disease and Parkinson's disease. With manufacturing capabilities, a broad product portfolio, and growing R&D capabilities, Gador represents a significant player in the Latin American pharmaceutical market. The company's focus on neuroscience and regional presence position it to continue serving patients across Argentina and Latin America with important therapeutic options.
[@gador2024]: [Gador Corporate Website](https://www.gador.com/) [@berger2023]: [Cholinesterase inhibitors in Alzheimer's disease therapy](https://pubmed.ncbi.nlm.nih.gov/37123456/) [@martinez2024]: [Novel CNS drug development for neurodegenerative diseases. CNS Drugs (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)